Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1.
CORTIFOAM vs HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Hydrocortisone acetate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, vasodilation, and immune cell activity. Pramoxine hydrochloride is a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, inhibiting nerve impulse conduction and providing topical anesthesia.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Apply a thin film to affected area three to four times daily. Topical only.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Hydrocortisone acetate: 1.5–2 hours (plasma), clinically adrenocortical suppression lasts 24–48 hours; pramoxine: not applicable due to minimal absorption.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Hydrocortisone acetate: primarily renal (about 90% as metabolites, less than 1% unchanged); pramoxine HCl: negligible systemic absorption, eliminated primarily via fecal excretion.
Category C
Category D/X
Corticosteroid
Corticosteroid